VBL Therapeutics announced that Ron Cohen, M.D., and Philip Serlin, C.P.A., were nominated to the Board of Directors VBL Therapeutics, a clinical-stage biotechnology company committed to the discovery, development, and commercialization of first-in-class treatments for cancer and immune-inflammatory disease.